Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, humanized CD40. Cifurtilimab shows antitumor activities[1][2].
Cifurtilimab 增强了 FcγRIIIa 结合 (比亲本 IgG1 抗体大 10 倍)，驱动效应因子功能的增强，导致比具有沉默或选择性 FcγR 结合的抗体更强的免疫刺激活性[1]。
暴露于 Cifurtilimab 会导致明显的反应特征，包括 APCs、CD8+ 和 CD4+ T 细胞和 NK 细胞的激活，以及 CD40+ B 细胞的靶向衰竭[1]。
在临床前小鼠模型中，Cifurtilimab 与化疗药物联合使用可增强抗肿瘤活性[2]。
[1]. Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.
[2]. Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020.